fluoxetine has been researched along with nicotine in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.32) | 18.7374 |
| 1990's | 3 (7.32) | 18.2507 |
| 2000's | 22 (53.66) | 29.6817 |
| 2010's | 12 (29.27) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, C; Caldwell, L; Kinnier, WJ; Lancaster, J; McMillan, B; Price, CH; Sweetnam, PM | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Keserü, GM | 1 |
| Caron, G; Ermondi, G | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Jia, L; Sun, H | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Crooks, PA; Deaciuc, AG; Dwoskin, LP; Grinevich, VP; Hojahmat, M; Horton, DB; Miller, DK; Norrholm, SD | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Allen, JM; Fairweather, I; Halton, DW; McKay, DM | 1 |
| Davidson, RK; Dilsauer, SC; Hariharen, M | 1 |
| Davidson, RK; Dilsaver, SC | 1 |
| Callaway, CW; Geyer, MA; Rempel, NL | 1 |
| Bjornsdottir, US; Blondal, T; Gudmundsson, LJ; Hilmarsdottir, H; Jonsdottir, D; Kristjansson, F; Nilsson, F; Tomasson, K | 1 |
| Branchek, TA; Calligaro, DO; Czachura, JF; Dreshfield-Ahmad, LJ; Evans, DC; Hemrick-Luecke, SK; Kallman, MJ; Kendrick, WT; Leander, JD; Nelson, DL; Overshiner, CD; Rasmussen, K; Wainscott, DB; Wolff, MC; Wong, DT; Xu, YC; Zgombick, JM | 1 |
| Downey, KK; Schuh, KJ; Schuh, LM; Stamat, HM | 1 |
| Harrison, AA; Liem, YT; Markou, A | 1 |
| Breitinger, HG; Geetha, N; Hess, GP | 1 |
| Jeong, MS; Kim, CJ; Kim, KW; Park, EY; Park, JW; Shin, BS; Shin, MS; Woo, RS; Zhao, RJ | 1 |
| Hurt, RD | 1 |
| Leslie, FM; O'Leary, KT | 1 |
| Caboche, J; Girault, JA; Hervé, D; Pagès, C; Valjent, E | 1 |
| Bonilla-Jaime, H; Vázquez-Palacios, G; Velázquez-Moctezuma, J | 2 |
| Harvey, I; Lilford, R; Song, F | 1 |
| Alcantara, LF; Bolaños-Guzmán, CA; Iñiguez, SD; Maffeo, ML; Manojlovic, Z; Parise, EM; Schuh, B; Warren, BL | 1 |
| Bifone, A; Gozzi, A; Schwarz, AJ | 1 |
| Bonilla-Jaime, H; Guevara Pérez, MA; Hernández-González, M; Vázquez-Palacios, G | 1 |
| Burgoon, LD; Johnstone, AF; Lin, BJ; Mack, CM; Shafer, TJ; Turner, JD | 1 |
| Alcantara, LF; Bolaños-Guzmán, CA; Iñiguez, SD; Parise, EM; Warren, BL | 1 |
| Satoh, N; Takahashi, K; Toyohira, Y; Yanagihara, N | 1 |
| Bernabeu, RO; Faillace, MP; Zwiller, J | 1 |
| Connor, DA; Gould, TJ | 1 |
| Braida, D; Dellarole, I; Morara, S; Ponzoni, L; Sala, M | 1 |
4 review(s) available for fluoxetine and nicotine
| Article | Year |
|---|---|
The role of receptor binding in drug discovery.
Topics: Animals; Drug Design; Humans; Receptors, Drug | 1993 |
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
Pharmacotherapy for alcoholic smokers.
Topics: Alcoholism; Animals; Fluoxetine; Humans; Nicotine; Smoking | 2002 |
Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bias; Bupropion; Data Interpretation, Statistical; Drug Therapy; Fluoxetine; Haloperidol; Humans; Imipramine; Meta-Analysis as Topic; Nicotine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Smoking Cessation; Treatment Outcome | 2008 |
2 trial(s) available for fluoxetine and nicotine
| Article | Year |
|---|---|
The effects of fluoxetine combined with nicotine inhalers in smoking cessation--a randomized trial.
Topics: Adult; Aged; Algorithms; Antidepressive Agents, Second-Generation; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Respiratory Therapy; Smoking Cessation | 1999 |
Subjective and discriminative stimulus effects of two de-nicotinized cigarettes with different tar yields.
Topics: Adult; Blood Pressure; Female; Fluoxetine; Heart Rate; Humans; Male; Middle Aged; Nicotine; Selective Serotonin Reuptake Inhibitors; Smoking Cessation; Smoking Prevention; Time Factors; Tobacco Use Disorder | 2001 |
35 other study(ies) available for fluoxetine and nicotine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters.
Topics: Animals; Esters; Ligands; Lobeline; Male; Molecular Structure; Neurons; Neurotransmitter Transport Proteins; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Stereoisomerism; Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The effects of cholinergic and serotoninergic drugs on motility in vitro of Haplometra cylindracea (Trematoda: Digenea).
Topics: Acetylcholine; Animals; Atropine; Carbachol; Fluoxetine; Methysergide; Movement; Nicotine; Parasympathomimetics; Physostigmine; Rana temporaria; Reserpine; Serotonin; Serotonin Antagonists; Trematoda; Tubocurarine | 1989 |
Desipramine subsensitizes nicotinic mechanism involved in regulating core temperature.
Topics: Amitriptyline; Animals; Body Temperature Regulation; Brain; Desipramine; Fluoxetine; Light; Lithium; Male; Nicotine; Phenelzine; Rats; Rats, Inbred Strains; Receptors, Nicotinic | 1988 |
Fluoxetine subsensitizes a nicotinic mechanism involved in the regulation of core temperature.
Topics: Animals; Antidepressive Agents; Body Temperature Regulation; Fluoxetine; Nicotine; Propylamines; Rats | 1987 |
Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Behavior, Animal; Caffeine; Designer Drugs; Dopamine Agents; Dose-Response Relationship, Drug; Fluoxetine; Indoles; Male; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Nicotine; Propranolol; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Scopolamine; Serotonin; Serotonin Receptor Agonists; Synapses | 1993 |
The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Acoustic Stimulation; Animals; Body Temperature; Columbidae; Corticosterone; Depression; Discrimination Learning; Drug Interactions; Fluoxetine; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Lip; Male; Microdialysis; Neurons; Nicotine; Piperidines; Posture; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Reflex, Startle; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Smoking Cessation; Substance Withdrawal Syndrome; Sulfur Radioisotopes | 2000 |
Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
Topics: Aminopyridines; Amphetamine; Amphetamine-Related Disorders; Animals; Body Weight; Brain; Depression; Disease Models, Animal; Drug Combinations; Electric Stimulation; Fluoxetine; Male; Mecamylamine; Neurons; Nicotine; Nicotinic Antagonists; Piperazines; Rats; Rats, Wistar; Reaction Time; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Reward; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Substance Withdrawal Syndrome; Synaptic Transmission; Tobacco Use Disorder | 2001 |
Inhibition of the serotonin 5-HT3 receptor by nicotine, cocaine, and fluoxetine investigated by rapid chemical kinetic techniques.
Topics: Animals; Binding Sites; Cocaine; Dose-Response Relationship, Drug; Drug Synergism; Electrophysiology; Fluoxetine; Kinetics; Mice; Nicotine; Patch-Clamp Techniques; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin Antagonists; Tumor Cells, Cultured | 2001 |
Mechanism of nicotine-evoked release of 3H-noradrenaline in human cerebral cortex slices.
Topics: Adolescent; Adult; Arginine; Calcium; Calcium Channel Blockers; Cerebral Cortex; Dihydro-beta-Erythroidine; Dizocilpine Maleate; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluoxetine; Ganglionic Stimulants; Guanylate Cyclase; Humans; In Vitro Techniques; Indazoles; Male; Mecamylamine; Methylene Blue; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Nicotine; Nicotinic Antagonists; Nitrendipine; Nitric Oxide Synthase; Norepinephrine; omega-Conotoxin GVIA; Oxadiazoles; Purinones; Quinoxalines; Tetrodotoxin; Tritium; Tubocurarine | 2002 |
Developmental regulation of nicotinic acetylcholine receptor-mediated [3H]norepinephrine release from rat cerebellum.
Topics: Age Factors; Aging; Animals; Animals, Newborn; Cerebellum; Dose-Response Relationship, Drug; Female; Fluoxetine; Gene Expression Regulation, Developmental; In Vitro Techniques; Male; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Symporters; Tritium | 2003 |
Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain.
Topics: Adrenergic Uptake Inhibitors; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Benzazepines; Brain; Caffeine; Central Nervous System Stimulants; Cocaine; Desipramine; Dopamine Antagonists; Dronabinol; Enzyme Activation; Fluoxetine; Immunohistochemistry; Male; Mice; Mitogen-Activated Protein Kinases; Morphine; Muscarinic Antagonists; Neurons; Nicotine; Nicotinic Agonists; Scopolamine; Selective Serotonin Reuptake Inhibitors | 2004 |
Antidepressant-like effects of the acute and chronic administration of nicotine in the rat forced swimming test and its interaction with fluoxetine [correction of flouxetine].
Topics: Animals; Antidepressive Agents; Depression; Drug Administration Schedule; Drug Interactions; Drug Synergism; Fluoxetine; Immobilization; Male; Motor Activity; Nicotine; Rats; Rats, Wistar; Swimming | 2004 |
Antidepressant effects of nicotine and fluoxetine in an animal model of depression induced by neonatal treatment with clomipramine.
Topics: Animals; Animals, Newborn; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Clomipramine; Depressive Disorder; Female; Fluoxetine; Injections, Subcutaneous; Motor Activity; Nicotine; Nicotinic Agonists; Pregnancy; Rats; Rats, Wistar; Serotonin; Swimming | 2005 |
Nicotine exposure during adolescence induces a depression-like state in adulthood.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cholinergic Agents; Depression; Emotions; Fluoxetine; Food Preferences; Male; Motor Activity; Nicotine; Rats; Rats, Sprague-Dawley; Reward; Stress, Psychological; Weight Gain | 2009 |
Community structure in networks of functional connectivity: resolving functional organization in the rat brain with pharmacological MRI.
Topics: Algorithms; Animals; Brain; Brain Mapping; Dextroamphetamine; Dopamine Uptake Inhibitors; Fluoxetine; Magnetic Resonance Imaging; Male; Neural Pathways; Nicotine; Nicotinic Agonists; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2009 |
Nicotine and fluoxetine induce arousing effects on sleep-wake cycle in antidepressive doses: a possible mechanism of antidepressant-like effects of nicotine.
Topics: Animals; Antidepressive Agents; Circadian Rhythm; Drug Interactions; Fluoxetine; Male; Nicotine; Nicotinic Agonists; Rats; Rats, Wistar; Sleep Stages; Time Factors; Wakefulness | 2010 |
Burst and principal components analyses of MEA data for 16 chemicals describe at least three effects classes.
Topics: Acetaminophen; Action Potentials; Animals; Cells, Cultured; Cerebral Cortex; Data Interpretation, Statistical; Fluoxetine; GABA Antagonists; Kainic Acid; Microelectrodes; Muscimol; Nerve Net; Neurons; Nicotine; Pesticides; Principal Component Analysis; Rats; Rats, Long-Evans; Verapamil | 2014 |
Effects of psychotropic drugs on second messenger signaling and preference for nicotine in juvenile male mice.
Topics: Animals; Cocaine; Conditioning, Psychological; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug-Seeking Behavior; Fluoxetine; Gene Expression; Male; MAP Kinase Signaling System; Methylphenidate; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Psychotropic Drugs; RNA, Messenger; Second Messenger Systems; Space Perception; Time Factors; Ventral Tegmental Area | 2014 |
Effects of various pharmacological agents on the function of norepinephrine transporter.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenergic Neurons; Animals; Cells, Cultured; Fluoxetine; Genistein; Humans; Ketamine; Nerve Endings; Nicotine; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Pentazocine; Sympathetic Nervous System; Synaptic Transmission | 2015 |
Effects of combined nicotine and fluoxetine treatment on adult hippocampal neurogenesis and conditioned place preference.
Topics: Animals; Conditioning, Psychological; Dentate Gyrus; Drug Interactions; Fluoxetine; Histone Deacetylase 2; Male; Nerve Tissue Proteins; Neurogenesis; Neurons; Nicotine; Nicotinic Agonists; Nucleus Accumbens; Rats, Sprague-Dawley; Receptors, Growth Factor; Receptors, Nerve Growth Factor; Reward; Selective Serotonin Reuptake Inhibitors; Spatial Behavior | 2015 |
Chronic fluoxetine ameliorates adolescent chronic nicotine exposure-induced long-term adult deficits in trace conditioning.
Topics: Aging; Animals; Anxiety; Brain-Derived Neurotrophic Factor; Conditioning, Psychological; Fear; Fluoxetine; Hippocampus; Learning Disabilities; Male; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Nootropic Agents; Prefrontal Cortex; Substance-Related Disorders | 2017 |
Fluoxetine rescues the depressive-like behaviour induced by reserpine and the altered emotional behaviour induced by nicotine withdrawal in zebrafish: Involvement of tyrosine hydroxylase.
Topics: Anhedonia; Animals; Calcitonin Gene-Related Peptide; Fluoxetine; Nicotine; Reserpine; Substance Withdrawal Syndrome; Tyrosine 3-Monooxygenase; Zebrafish | 2023 |